| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/22/2007 | WO2007021629A2 Non-nucleoside reverse transcriptase inhibitors |
| 02/22/2007 | WO2007021610A2 Ribonucleoside cyclic acetal derivatives for the treatment of rna-dependent rna viral infection |
| 02/22/2007 | WO2007021574A1 Bicyclic piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | WO2007021573A1 Substituted piperazines as metabotropic glutamate receptor antagonists |
| 02/22/2007 | WO2007021545A2 Piperazine derivatives |
| 02/22/2007 | WO2007021529A1 Use of choline to prevent thrombosis associated with total parenteral nutrition |
| 02/22/2007 | WO2007021504A2 Methods for prophylactic and therapeutic nutritional supplementation |
| 02/22/2007 | WO2007021499A2 Antimicrobial polymers |
| 02/22/2007 | WO2007021464A1 Hindered cyclic polyamines and their salts for acid gas scrubbing process |
| 02/22/2007 | WO2007021460A2 Method of reducing adverse cardiovascular events |
| 02/22/2007 | WO2007021309A1 Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| 02/22/2007 | WO2007021262A1 USE OF ß-1,3 (4)-ENDOGLUCANOHYDROLASE, ß-1,3 (4) GLUCAN, DIATOMACEOUS EARTH, MINERAL CLAY AND GLUCOMANNAN TO AUGMENT IMMUNE FUNCTION |
| 02/22/2007 | WO2007021234A1 Boron compounds useful in bnct |
| 02/22/2007 | WO2007021189A2 Method of treating parturient placental mammals in order to reduce maternal and/or utirine exhaustion |
| 02/22/2007 | WO2007021168A1 Sublingual solid pharmaceutical formulations containing meloxicam |
| 02/22/2007 | WO2007021167A1 Pharmaceutical formulations in the form of solids, semisolids, in suspension, in solution, in emulsion or in syrup, containing clindamycin and one or more members of the azole family |
| 02/22/2007 | WO2007021164A1 Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium |
| 02/22/2007 | WO2007021072A1 Metformin tablet with sustained release and method for preparing the same |
| 02/22/2007 | WO2007021061A1 Composition comprising oleic acid and the use thereof |
| 02/22/2007 | WO2007021020A1 Capsinoid containing composition |
| 02/22/2007 | WO2007020936A1 Bicyclo heterocyclic compound having antifungal action |
| 02/22/2007 | WO2007020935A1 Therapeutic agent for pain comprising p2y12 receptor and/or p2y14 receptor blocker |
| 02/22/2007 | WO2007020917A1 Agent for enhancing and prolonging utrophin production and processed food comprising the same |
| 02/22/2007 | WO2007020888A1 Brain/neuronal cell-protecting agent, and therapeutic agent for sleep disorder |
| 02/22/2007 | WO2007020877A1 Anthranilamide compounds, process for producing these, and pest control agent comprising any of these |
| 02/22/2007 | WO2007020873A1 Nucleic acid for treatment or prevention of immunodeficiency virus infection |
| 02/22/2007 | WO2007020673A1 Use of glucosylated hydroxystilbenes for the prevention and treatment of eye pathologies |
| 02/22/2007 | WO2007020671A2 Ophthalmic compositions containing mucoadhesive polysaccharides able to promote corneal re-epithelization |
| 02/22/2007 | WO2007020653A1 Thioether derivatives as functional 5-ht6 ligands |
| 02/22/2007 | WO2007020652A1 Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands. |
| 02/22/2007 | WO2007020642A2 A method of preparing functionalized molecularly imprinted polymers using labile linking |
| 02/22/2007 | WO2007020631A2 Tetracyclic benzofuran derivatives with therapeutic activities |
| 02/22/2007 | WO2007020533A2 Process for the preparation of losartan potassium |
| 02/22/2007 | WO2007020521A1 Pyridoyrazinones as pde-5 inhibitors |
| 02/22/2007 | WO2007020509A1 Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth |
| 02/22/2007 | WO2007020479A2 Pharmaceutical compositions comprising metals for modulating epithelial cell-to-cell adhesion |
| 02/22/2007 | WO2007020426A1 Pyrazolone derivatives for the treatment of tuberculosis |
| 02/22/2007 | WO2007020421A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | WO2007020413A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | WO2007020411A1 Amide derivatives |
| 02/22/2007 | WO2007020403A1 Azapeptides for treating hyperalgesic pain conditions |
| 02/22/2007 | WO2007020400A1 Fluorination process of anilide derivatives and benzothiazole fluorinate derivatives as in vivo imaging agents |
| 02/22/2007 | WO2007020388A1 Pyrazole derivatives as therapeutic agents |
| 02/22/2007 | WO2007020365A1 The ocean wave energy converter (owec) |
| 02/22/2007 | WO2007020349A1 Oil-in-water-type emulsion for topical application in dermatology |
| 02/22/2007 | WO2007020348A1 Proanthocyanidin tannin composition, production method thereof and use of same |
| 02/22/2007 | WO2007020344A1 Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
| 02/22/2007 | WO2007020343A1 Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics |
| 02/22/2007 | WO2007020337A1 Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same |
| 02/22/2007 | WO2007020286A2 Method of using potassium channel inhibiting compounds |
| 02/22/2007 | WO2007020261A2 Selected cgrp antagonists, methods for the production thereof and their use as medicaments |
| 02/22/2007 | WO2007020213A2 Thiazolyl piperidine derivatives useful as h3 receptor modulators |
| 02/22/2007 | WO2007020195A2 Peg-ifn alpha and ribavirin for hbv treatment |
| 02/22/2007 | WO2007020194A1 Piperidine and piperazine derivatives as p2x3 antagonists |
| 02/22/2007 | WO2007020190A1 Fluoro substituted 2-oxo azepan derivatives |
| 02/22/2007 | WO2007020085A2 Compositions containing taxane derivatives for intravenous injection |
| 02/22/2007 | WO2007020046A1 Benzoquinazoline derivatives and their use in treating bone disorders |
| 02/22/2007 | WO2007020042A1 Use of 25-hydroxy vitamin d3 to improve male animal fertility |
| 02/22/2007 | WO2007020018A1 Use of purinergic and pyrimidinergic receptor agonists for dendritic cells based immunotherapies |
| 02/22/2007 | WO2007020009A1 New crystalline form of perindopril erbumine |
| 02/22/2007 | WO2007019987A1 Substituted 8-(3-aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-on-derivatives for use in pain therapy |
| 02/22/2007 | WO2007019933A1 1-acyldihydropyrazol derivatives |
| 02/22/2007 | WO2007019914A1 Use of thienopyridone derivatives as ampk activators and pharmaceutical compositions containing them |
| 02/22/2007 | WO2007019888A2 Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases |
| 02/22/2007 | WO2007019884A1 Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
| 02/22/2007 | WO2007019880A1 Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome |
| 02/22/2007 | WO2007019874A1 Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles |
| 02/22/2007 | WO2007019867A1 Novel 2,3-dihydroindole compounds |
| 02/22/2007 | WO2007019678A1 Methods and devices for lymphatic targeting |
| 02/22/2007 | WO2007019675A1 Indole derivatives as crth2 receptor antagonists |
| 02/22/2007 | WO2007019674A1 Viral polymerase inhibitors |
| 02/22/2007 | WO2007019661A1 Supplemental dietary composition for enhancing muscle performance and/or recovery from fatigue |
| 02/22/2007 | WO2007005961A3 Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| 02/22/2007 | WO2007002862A3 Compositions and methods for treatment of cycle-related symptoms |
| 02/22/2007 | WO2007002764A3 Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
| 02/22/2007 | WO2007002447A3 Compositions for treating rosacea |
| 02/22/2007 | WO2007001455A9 Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants |
| 02/22/2007 | WO2007001194A3 Parenteral selenomethionine for production of selenium-rich foods |
| 02/22/2007 | WO2007000550A3 Novel indoline compounds |
| 02/22/2007 | WO2006138202A3 Pharmaceutical formulations for minimizing drug-drug interactions |
| 02/22/2007 | WO2006134486A3 Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
| 02/22/2007 | WO2006134279A3 Method for solubilizing metronidazole |
| 02/22/2007 | WO2006134163A8 Novel tetracyclic tetrahydrofuran derivatives containing a cyclic amine side chain |
| 02/22/2007 | WO2006133006A3 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents |
| 02/22/2007 | WO2006130160A3 Furanopyridine derivatives as ack1 and lck modulators |
| 02/22/2007 | WO2006128679A3 Phosphatidylinositol composition and 3'-phosphorylated lysophosphatidylinositols in the treatment of cancer and autoimmune diseases |
| 02/22/2007 | WO2006127379A3 Par2-modulating compounds and their use |
| 02/22/2007 | WO2006127217A3 Cyclopropanecarboxylate esters of acyclovir |
| 02/22/2007 | WO2006124695A3 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives combined with another drug for lowering intraocular pressure |
| 02/22/2007 | WO2006122777A3 Use of 2,5-disubstituted thiazol-4-one derivatives in drugs |
| 02/22/2007 | WO2006121742A3 Formulations of a src/abl inhibitor |
| 02/22/2007 | WO2006120252A3 Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof |
| 02/22/2007 | WO2006119402A3 C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth |
| 02/22/2007 | WO2006119389A3 Quinine-containing controlled-release formulations |
| 02/22/2007 | WO2006119313A3 6-11 bridged oxime erythromycin derivatives |
| 02/22/2007 | WO2006117299A3 Novel crystalline forms of tiotropium bromide |
| 02/22/2007 | WO2006116591A3 Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof |
| 02/22/2007 | WO2006116218A8 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride |
| 02/22/2007 | WO2006113990A3 LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1α ,25-DIHYDROXY VITAMIN D3 |
| 02/22/2007 | WO2006113557A3 Gpcr modulators |